Eylea Label For Retinopathy Of Prematurity Should Specify ‘Treatment Tradeoff’ Versus Laser
Executive Summary
US FDA advisory committee recommends ‘more granularity’ in label on administration of Eylea in premature infants. Specifying intervals between injections is important for insurance coverage, agency official notes.
You may also be interested in...
FDA Seems Set To Label Eylea For Retinopathy Of Prematurity Despite Failed Primary Endpoint
Two studies failed to demonstrate that Eylea was non-inferior to laser treatment. Agency says compared to the expected natural history, there is a ‘clear beneficial effect’ of Eylea which also maintains peripheral vision. Advisory committee to discuss how to convey findings in label.
Pharmacies Likely To Cease Prescribing COVID-19 Therapeutics With End Of Public Health Emergency
Existing emergency use authorizations to remain in effect and FDA may continue to issue new ones. Pfizer and Merck are moving to transition Paxlovid and Lagevrio to full approval as FDA allows prescribing without a positive COVID test first.
FDA Urged To Collaborate With USPTO On Orange Book Listings, Eliminate Patent Use Codes
Stakeholders suggest a variety of USPTO and FDA actions that could help ensure patents do not improperly delay generic and biosimilar competition.